PortalPublikationenIntragastric acidity during treatment with esomeprazole 40 m...

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study

Standard

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study. / Miehlke, S; Madisch, A; Kirsch, C; Lindner, F; Kuhlisch, E; Laass, M; Knoth, H; Morgner, A; Labenz, J.

in: ALIMENT PHARM THER, Jahrgang 21, Nr. 8, 15.04.2005, S. 963-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Miehlke, S, Madisch, A, Kirsch, C, Lindner, F, Kuhlisch, E, Laass, M, Knoth, H, Morgner, A & Labenz, J 2005, 'Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study', ALIMENT PHARM THER, Jg. 21, Nr. 8, S. 963-7. https://doi.org/10.1111/j.1365-2036.2005.02432.x

APA

Miehlke, S., Madisch, A., Kirsch, C., Lindner, F., Kuhlisch, E., Laass, M., Knoth, H., Morgner, A., & Labenz, J. (2005). Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study. ALIMENT PHARM THER, 21(8), 963-7. https://doi.org/10.1111/j.1365-2036.2005.02432.x

Vancouver

Miehlke S, Madisch A, Kirsch C, Lindner F, Kuhlisch E, Laass M et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study. ALIMENT PHARM THER. 2005 Apr 15;21(8):963-7. https://doi.org/10.1111/j.1365-2036.2005.02432.x

Bibtex

@article{75d1e9a9ca9e43418fb74b5148b87294,
title = "Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study",
abstract = "BACKGROUND: Patients with severe or complicated reflux disease may require higher than standard doses of a proton pump inhibitor for sufficient acid suppression.AIM: To test the hypothesis that esomeprazole 40 mg twice daily is superior to pantoprazole 40 mg twice daily in lowering intragastric acidity.METHODS: In a randomized, single-blinded, two-way crossover study, healthy subjects received esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily orally for five consecutive days. Continuous ambulatory 24-h intragastric pH was recorded on day 5 of each treatment.RESULTS: Thirty subjects were analysed. Esomeprazole provided significantly higher intragastric pH-values over the 24-h period [median intragastric pH 6.4 for esomeprazole and 5.1 for pantoprazole (P < 0.00005)]. Intragastric pH > 4 was maintained for 21.1 h with esomeprazole and 16.8 h with pantoprazole (P < 0.0001). An intragastric pH > 4 for more than 16 h was achieved in 96.7 and 56.7% of subjects, respectively (P = 0.0002). During night-time the proportion of time with intragastric pH > 4 was 85.4% with esomeprazole and 63.6% with pantoprazole (P = 0.0001). Nocturnal acid break through occurred less frequently on esomeprazole.CONCLUSIONS: Esomeprazole 40 mg twice daily provides better and more consistent intragastric acid control than pantoprazole 40 mg twice daily.",
keywords = "2-Pyridinylmethylsulfinylbenzimidazoles, Adult, Anti-Ulcer Agents, Benzimidazoles, Cross-Over Studies, Esomeprazole, Female, Gastric Acid, Gastric Acidity Determination, Humans, Hydrogen-Ion Concentration, Male, Middle Aged, Proton Pump Inhibitors, Single-Blind Method, Sulfoxides, Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial",
author = "S Miehlke and A Madisch and C Kirsch and F Lindner and E Kuhlisch and M Laass and H Knoth and A Morgner and J Labenz",
year = "2005",
month = apr,
day = "15",
doi = "10.1111/j.1365-2036.2005.02432.x",
language = "English",
volume = "21",
pages = "963--7",
journal = "ALIMENT PHARM THER",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study

AU - Miehlke, S

AU - Madisch, A

AU - Kirsch, C

AU - Lindner, F

AU - Kuhlisch, E

AU - Laass, M

AU - Knoth, H

AU - Morgner, A

AU - Labenz, J

PY - 2005/4/15

Y1 - 2005/4/15

N2 - BACKGROUND: Patients with severe or complicated reflux disease may require higher than standard doses of a proton pump inhibitor for sufficient acid suppression.AIM: To test the hypothesis that esomeprazole 40 mg twice daily is superior to pantoprazole 40 mg twice daily in lowering intragastric acidity.METHODS: In a randomized, single-blinded, two-way crossover study, healthy subjects received esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily orally for five consecutive days. Continuous ambulatory 24-h intragastric pH was recorded on day 5 of each treatment.RESULTS: Thirty subjects were analysed. Esomeprazole provided significantly higher intragastric pH-values over the 24-h period [median intragastric pH 6.4 for esomeprazole and 5.1 for pantoprazole (P < 0.00005)]. Intragastric pH > 4 was maintained for 21.1 h with esomeprazole and 16.8 h with pantoprazole (P < 0.0001). An intragastric pH > 4 for more than 16 h was achieved in 96.7 and 56.7% of subjects, respectively (P = 0.0002). During night-time the proportion of time with intragastric pH > 4 was 85.4% with esomeprazole and 63.6% with pantoprazole (P = 0.0001). Nocturnal acid break through occurred less frequently on esomeprazole.CONCLUSIONS: Esomeprazole 40 mg twice daily provides better and more consistent intragastric acid control than pantoprazole 40 mg twice daily.

AB - BACKGROUND: Patients with severe or complicated reflux disease may require higher than standard doses of a proton pump inhibitor for sufficient acid suppression.AIM: To test the hypothesis that esomeprazole 40 mg twice daily is superior to pantoprazole 40 mg twice daily in lowering intragastric acidity.METHODS: In a randomized, single-blinded, two-way crossover study, healthy subjects received esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily orally for five consecutive days. Continuous ambulatory 24-h intragastric pH was recorded on day 5 of each treatment.RESULTS: Thirty subjects were analysed. Esomeprazole provided significantly higher intragastric pH-values over the 24-h period [median intragastric pH 6.4 for esomeprazole and 5.1 for pantoprazole (P < 0.00005)]. Intragastric pH > 4 was maintained for 21.1 h with esomeprazole and 16.8 h with pantoprazole (P < 0.0001). An intragastric pH > 4 for more than 16 h was achieved in 96.7 and 56.7% of subjects, respectively (P = 0.0002). During night-time the proportion of time with intragastric pH > 4 was 85.4% with esomeprazole and 63.6% with pantoprazole (P = 0.0001). Nocturnal acid break through occurred less frequently on esomeprazole.CONCLUSIONS: Esomeprazole 40 mg twice daily provides better and more consistent intragastric acid control than pantoprazole 40 mg twice daily.

KW - 2-Pyridinylmethylsulfinylbenzimidazoles

KW - Adult

KW - Anti-Ulcer Agents

KW - Benzimidazoles

KW - Cross-Over Studies

KW - Esomeprazole

KW - Female

KW - Gastric Acid

KW - Gastric Acidity Determination

KW - Humans

KW - Hydrogen-Ion Concentration

KW - Male

KW - Middle Aged

KW - Proton Pump Inhibitors

KW - Single-Blind Method

KW - Sulfoxides

KW - Clinical Trial

KW - Comparative Study

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1111/j.1365-2036.2005.02432.x

DO - 10.1111/j.1365-2036.2005.02432.x

M3 - SCORING: Journal article

C2 - 15813831

VL - 21

SP - 963

EP - 967

JO - ALIMENT PHARM THER

JF - ALIMENT PHARM THER

SN - 0269-2813

IS - 8

ER -